// App-Quantinova.ai

860 : First-in-Human Phase 1/2 Clinical Trial of SIG-001, an Innovative Shielded Cell Therapy Platform, for Hemophilia Α

Researchers

Presenter

  • Amy D Shapiro

Principal Investigators

  • Barbara A. Konkle

  • Stacy E. Croteau

  • Wolfgang A. Miesbach

  • Charles Richard Morris Hay

  • Rashid Kazmi

  • Marina Mihova

  • Savita Rangarajan

  • John Pasi

Medical Centers

  • Indiana Hemophilia & Thrombosis Center, Indianapolis, IN

  • University of Washington, Seattle, WA

  • University of Washington, Washington Center for Bleeding Disorders, Seattle, WA

  • Boston Children's Hospital, Boston, MA

  • Haemophilia Centre, University Hospital Frankfurt, Frankfurt, Germany

  • Manchester Royal Infirmary, Manchester, United Kingdom

  • University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom

  • Jounce Therapeutics, Cambridge, MA

  • University Hospital Southampton NHS Foundation Trust, Southampton, United KingdomCancer Research UK, Southampton, United Kingdom

  • Barts and the London School of Medicine, London, United Kingdom

Locations

  • United States

  • Germany

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Hemophilia

Biomarkers

  • N/A

Drug/Treatment

  • SIG-001

  • FVIII

Outcome

  • N/A

Study Design

  • Open Label

  • Multicenteric

  • Cohort

  • First-In-Human

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved